SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+2.97%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$1.09B
AUM Growth
+$1.09B
(+13%)
Cap. Flow
+$158M
Cap. Flow
% of AUM
14.49%
Top 10 Holdings %
Top 10 Hldgs %
43.03%
Holding
204
New
91
Increased
35
Reduced
20
Closed
37
Top Buys
| 1 |
Sanofi
SNY
|
$49.4M |
| 2 |
AbbVie
ABBV
|
$28.1M |
| 3 |
Johnson & Johnson
JNJ
|
$19M |
| 4 |
LivePerson
LPSN
|
$13.7M |
| 5 |
AstraZeneca
AZN
|
$13.4M |
Top Sells
| 1 |
Novartis
NVS
|
$40.5M |
| 2 |
Bristol-Myers Squibb
BMY
|
$26.8M |
| 3 |
Sarepta Therapeutics
SRPT
|
$12.8M |
| 4 |
Zymeworks
ZYME
|
$11.6M |
| 5 |
Meta Platforms (Facebook)
META
|
$10.9M |
Sector Composition
| 1 | Healthcare | 74.93% |
| 2 | Technology | 9.21% |
| 3 | Industrials | 5.88% |
| 4 | Financials | 3.51% |
| 5 | Consumer Discretionary | 1.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$657B
| $80.2M | 6.15% | 429,200 +19,200 | +5% | +$3.59M |
|
|
2
Johnson & Johnson
JNJ
$427B
| $74.6M | 5.72% | 453,900 +115,700 | +34% | +$19M |
|
|
3
AbbVie
ABBV
$372B
| $64.9M | 4.98% | 599,500 +259,500 | +76% | +$28.1M |
|
4
Merck
MRK
$210B
| $62.4M | 4.78% | 808,808 +80,000 | +11% | +$6.17M |
|
|
5
Sanofi
SNY
$121B
| $49.4M | 3.79% | +997,900 | New | +$49.4M |
|
|
6
AstraZeneca
AZN
$248B
| $47.8M | 3.66% | 960,473 +270,000 | +39% | +$13.4M |
|
7
Generac Holdings
GNRC
$10.9B
| $34.6M | 2.65% | 105,663 | – | – |
|
8
Kura Oncology
KURA
$686M
| $20.3M | 1.56% | 717,751 +246,257 | +52% | +$6.96M |
|
9
C4 Therapeutics
CCCC
$185M
| $18.4M | 1.41% | 497,136 +53,312 | +12% | +$1.97M |
|
10
Microsoft
MSFT
$3.77T
| $15.9M | 1.22% | 67,536 +20,000 | +42% | +$4.72M |
|
11
Kornit Digital
KRNT
$669M
| $14.7M | 1.13% | 148,381 +20,000 | +16% | +$1.98M |
|
12
Syndax Pharmaceuticals
SNDX
$1.41B
| $14.3M | 1.09% | 638,093 -107,807 | -14% | -$2.41M |
|
|
13
LivePerson
LPSN
$90.1M
| $13.7M | 1.05% | +260,000 | New | +$13.7M |
|
14
ESSA Pharma
EPIX
$11.4M
| $13.6M | 1.05% | 469,241 +79,041 | +20% | +$2.3M |
|
15
AudioCodes
AUDC
$273M
| $12.8M | 0.98% | 475,624 +46,653 | +11% | +$1.26M |
|
|
16
Bristol-Myers Squibb
BMY
$96B
| $12.6M | 0.97% | 200,000 -425,000 | -68% | -$26.8M |
|
|
ONCR
17
DELISTED
Oncorus, Inc.
ONCR
| $12.6M | 0.96% | 903,111 | – | – |
|
|
CERE
18
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $12.5M | 0.96% | 912,240 +100,575 | +12% | +$1.38M |
|
19
Palo Alto Networks
PANW
$127B
| $10.4M | 0.8% | 32,300 -5,571 | -15% | -$1.79M |
|
|
SWTX
20
DELISTED
SpringWorks Therapeutics
SWTX
| $10.1M | 0.78% | 137,672 +106,372 | +340% | +$7.83M |
|
21
Curis
CRIS
$20.9M
| $10M | 0.77% | +885,838 | New | +$10M |
|
|
ORTX
22
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $9.92M | 0.76% | +1,366,564 | New | +$9.92M |
|
23
Kymera Therapeutics
KYMR
$2.95B
| $9.62M | 0.74% | 247,527 +99,827 | +68% | +$3.88M |
|
24
ALX Oncology
ALXO
$62.7M
| $9.61M | 0.74% | 130,351 -3,097 | -2% | -$228K |
|
25
Teva Pharmaceuticals
TEVA
$21.1B
| $9.61M | 0.74% | 832,878 | – | – |
|